Basking Ridge, NJNCT07635238Now EnrollingIRB Ready

Prostate Cancer Clinical Trial in Basking Ridge, NJ

Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Basking Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Basking Ridge location

Preparing your pre-screening questions…

Expert Care in Basking Ridge

Access prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer treatment provided free

Apply for This Basking Ridge Location

Check if you qualify for this prostate cancer clinical trial in Basking Ridge, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Basking Ridge

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Basking Ridge site if eligible
  4. 4Begin participation

About This Prostate Cancer Study in Basking Ridge

The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Documentation of Disease o Patients must have pathologically confirmed prostate adenocarcinoma.
Definition of Disease
Grade Group (GG) 1, 2, or 3.
PSA less than 20 ng/mL prior to starting ADT, if used.
Clinical stage of TX, T1 or T2 on digital rectal examination. May have up to radiological stage T3a on MRI. MRI must be performed within 12 months of randomization.
MRI-visible tumor(s), all having PIRADS v2.1 scores of 3, 4, or 5. Each tumor should be able to be delineated on T2 and diffusion-weighted imaging (DWI) +/- dynamic contrast-enhanced imaging (DCE).
Tumor nodule visible on MRI should be considered able to be boosted by treating clinician (ie meet urethral constraints while maintaining mandatory GTV coverage) and \<2.5cm in maximal dimension.
The MRI-defined lesion must be confirmed as malignant on biopsies (Grade group 1, 2, or 3).
Patients can be concurrently treated with androgen deprivation therapy (ADT) if this would be standard of care. LHRH analogues, LHRH agonists or Bicalutamide are permitted. ADT is not mandatory where this would usually be omitted. Patients needing greater than 6 months of ADT due to disease parameters should be excluded.
No high grade disease (GG3) occult to MRI-defined lesion. As a guide, any pathology for which you would consider surveillance (e.g. GG1, low volume GG2) is allowed outside of the MRI-defined area.
No contraindications to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia).
Prostate volume less than or equal to 90mL.
No evidence of nodal or distant metastatic disease.
Prior Treatment o No history of previous radiation to the prostate, prostate surgery (including transurethral resection of the prostate (TURP)), or other local prostate cancer treatments.
ECOG Performance Status of ≤ 2 (See Appendix I for performance status criteria)
Required Organ Function
Adequate hematologic function defined as follows:
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
Platelets ≥ 100,000 cells/mm3
Hemoglobin ≥ 8 g/dl
Adequate renal function defined as follows:
Creatinine clearance (CrCL) of ≥30 mL/min by the Cockcroft-Gault formula: CrCl (mL/min) = \[140 - age (years)\] x weight (kg) / 72 x creatinine (mg / dL) {x 0.85 for female patients}
Adequate hepatic function defined as follows:
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
AST and ALT ≤3 x institutional ULN
Adequate cardiac function defined as follows:
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
To be eligible for this trial, patients should be class 2B or better (see Appendix II: New York Heart Association (NYHA) Functional Classification).
Comorbid Conditions
No active infection requiring parenteral antibiotic(s).
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
No severe GU symptoms that would preclude extreme hypofractionation per the discretion of the treating physician.
No IPSS Score greater than 19.
No comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up.
Ability of the participant to understand and the willingness to sign a written informed consent form.
Willing to consent to contraception during and for 1 year after treatment when applicable.
Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Basking Ridge?

Yes, this clinical trial (NCT07635238) has an active research site in Basking Ridge, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer Treatment Options in Basking Ridge, NJ

If you're searching for prostate cancer treatment options in Basking Ridge, NJ, this clinical trial (NCT07635238) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Basking Ridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Basking Ridge, NJ

See all prostate cancer clinical trials recruiting in Basking Ridge — not just this study.

Browse Prostate Cancer Trials in Basking Ridge →

Browse More Trials by Condition

Prostate Cancer TrialsAll Conditions →

Ready to Join in Basking Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Basking Ridge, NJ